Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
Incorporation of maintenance therapy with PARP inhibitors after first‑line chemotherapy in high‑grade serous or endometrioid ovarian cancer should be considered as part of the reference arm, at least for patients with germline or somatic BRCA mutations or BRCA‑wild‑type tumours with HR‑deficiency.
This consensus conference presents evidence‑based recommendations for the design of ovarian cancer clinical trials, focusing on first‑line treatment, recurrent disease, and unmet needs, emphasizing the role of maintenance PARP inhibitors and angiogenesis inhibitors, and the importance of biomarker‑driven stratification.
These recommendations aim to harmonise clinical trial design worldwide, accelerating therapeutic advances and improving patient outcomes for ovarian cancer patients.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
- Ovarian cancer – Treatment – Overview of Information and Clinical Research